Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is “the ...

COVID-19 vaccines for children between the ages of 5 and 11 could get the green light from the US Food and Drug Administration sometime this fall, Dr. Anthony Fauci said. "If you look at the studies ...

KALAMAZOO, Mich. -- Even though U.S. health officials authorized the emergency use of Pfizer's COVID-19 vaccine, getting the pandemic under control will take time and effort. One of the biggest steps ...

By Blake Brittain Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology ...

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...